Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer

Video

In Partnership With:

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Related Videos
Jose A. Karam, MD, FACS
Amer Zeidan, MBBS
Eric Jonasch, MD
Ulka Nitin Vaishampayan, MBBS
Erica L. Mayer, MD, MPH
Christopher M. Gallagher, MD
Lyudmila A. Bazhenova, MD
Benjamin Philip Levy, MD
John N. Allan, MD
Nicole Lamanna, MD
Related Content
Biagio Ricciuti, MD

Long-Term Survival Benefit With PD-1 Monotherapy Correlated With High PD-L1 Expression in Advanced NSCLC

November 29th 2023
Article
USC Norris Comprehensive Cancer Center, UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Fox Chase Cancer Center, the University of Chicago Comprehensive Cancer Center

Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials

May 1st 2023
Podcast
EO2401 Plus Nivolumab and Bevacizumab Shows Activity in Progressive/Recurrent Glioblastoma

EO2401 Plus Nivolumab and Bevacizumab Shows Activity in Progressive/Recurrent Glioblastoma

November 20th 2023
Article
Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023
Podcast
© stock.adobe.com

Volrustomig Demonstrates Activity in Treatment-Naive Advanced ccRCC

November 16th 2023
Article
© stock.adobe.com

Durvalumab Plus Chemo Wins Approval in China For Advanced/Metastatic Biliary Tract Cancer

November 14th 2023
Article